This edition of Drug Discovery Technology, depicts the current landscape and the drug discovery trends across colorectal cancer therapeutics. Responsible for about 700,000 deaths every year worldwide, both the scientific and clinical community exhibit great concern about colorectal cancer, which is evidenced in the most innovative developments carried out across the world. Special emphasis has been focused on the use of adjacent technologies such as nanotech-based developments, as well as, the discovery of new biochemical mechanisms to inhibit specific pathways associated with tumor growth. Patent analysis is also presented, depicting the intellectual property scenario in the field of colorectal cancer therapeutics.
The Drug Discovery Technology TechVision Opportunity Engine (TOE) reports and analyzes about the latest developments in drug discovery and therapeutics, thereby providing an opportunity to acquire strategic insights into crucial developments in this industry domain. Technologies profiled include those used for biomarker and target discovery such as high throughput screening, signal transduction, micro array, RNAi, metabolomics, toxicogenomics, biosensors and nanotechnology. In addition to these, a fair focus shall be dedicated to the latest trends in therapeutic approaches across a diversity of diseases including infectious, genetic, metabolic, neurological, cardiac, and autoimmune disorders.
The Health and Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.
Keywords: Colorectal cancer, liquid biopsy, exosome-based assays, cancer therapeutics, ligands, Wnt/beta-catenin inhibitors, beta-carbolines, beta-glucan, vascular endothelial growth factor